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Introduction
The publication of the Global Burden
of Disease Study 2010 (GBD 2010) and
the accompanying collection of Lancet
articles in December 2012 provided the
most comprehensive attempt to quantify
the burden of almost 300 diseases,
injuries, and risk factors, including ne-
glected tropical diseases (NTDs) [1–3].
The disability-adjusted life year (DALY),
the metric used in the GBD 2010, is a tool
which may be used to assess and compare
the relative impact of a number of
diseases locally and globally [4–6].
Table 1 lists the major NTDs as defined
by the World Health Organization
(WHO) [7] and their estimated DALYs
[1]. With a few exceptions, most of the
NTDs currently listed by the WHO [7] or
those on the expanded list from PLOS
Neglected Tropical Diseases [8] are dis-
ablers rather than killers, so the DALY
estimates represent one of the few metrics
available that could fully embrace the
chronic effects of these infections.
Even DALYs, however, do not tell the
complete story of the harmful effects
from NTDs. Some of the specific and
potential shortcomings of GBD 2010
have been highlighted elsewhere [9].
Furthermore, DALYs measure only di-
rect health loss and, for example, do not
consider the economic impact of the
NTDs that results from detrimental
effects on school attendance and child
development, agriculture (especially from
zoonotic NTDs), and overall economic
productivity [10,11]. Nor do DALYs
account for direct costs of treatment,
surveillance, and prevention measures.
Yet, economic impact has emerged as an
essential feature of the NTDs, which may
trap people in a cycle of poverty and
disease [10–12]. Additional aspects not
considered by the DALY metrics are the
important elements of social stigma for
many of the NTDs and the spillover
effects to family and community mem-
bers [13,14], loss of tourism [15], and
health system overload (e.g., during
dengue outbreaks). Ultimately NTD
control and elimination efforts could
produce social and economic benefits
not necessarily reflected in the DALY
metrics, especially among the most
affected poor communities [11].
Variations in DALYs
Despite the importance of the concept
of disease burden and disability to the
NTD community, assigning DALYs or
related metrics to each NTD has been a
bit of a roller-coaster ride over the past
decade and may continue to be for many
years to come. Significant variations in
ascribing DALYs to the NTDs are due to
many factors, including data scarcity and
inherent difficulties in accurately estimat-
ing the number of individuals at risk, the
number of incident cases, the number of
prevalent cases, and, among these, the
duration of the infection. Challenges also
include uncertainty about the relationship
between acute and chronic infections and
their link to specific morbidities, duration
of morbidity, and the proportion of the
population infected or with morbidities
Citation: Hotez PJ, Alvarado M, Basa´n˜ez M-G, Bolliger I, Bourne R, et al. (2014) The Global Burden of Disease
Study 2010: Interpretation and Implications for the Neglected Tropical Diseases. PLoS Negl Trop Dis 8(7): e2865.
doi:10.1371/journal.pntd.0002865
Editor: Nilanthi de Silva, University of Kelaniya, Sri Lanka
Published July 24, 2014
Copyright:  2014 Hotez et al. This is an open-access article distributed under the terms of the Creative
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
Funding: The authors have indicated that no funding was received for this work.
Competing Interests: I have read the journal’s policy and have the following conflicts: ASB is employed by a
commercial company, Inovio Pharmaceuticals. This does not alter our adherence to all PLOS NTDs policies on
sharing data and materials. There are no other competing interests to declare.
* Email: hotez@bcm.edu (PJH); cjlm@uw.edu (CJLM); nagham@uw.edu (MN)
. These authors contributed equally to this work.
PLOS Neglected Tropical Diseases | www.plosntds.org 1 July 2014 | Volume 8 | Issue 7 | e2865
that are treated versus untreated. An
additional challenge is to obtain all of the
aforementioned values stratified by age
and gender, data which are seldom
available for NTDs. Moreover, the afford-
able diagnostic tools typically used to
measure NTDs in resource-constrained
settings are inaccurate and many sequelae
(i.e., morbidities) of NTDs are nonspecific,
making it difficult to attribute them to a
particular infection or risk factor. For
several NTDs, controversies remain re-
garding what proportion of a sequelae
should be ascribed to different infections
or diseases. An extreme example is the
case of schistosomiasis, for which disease
burden estimates over the past decade
have ranged from 1.7 million DALYs to as
many as 56 million DALYs, depending on
whether higher disease prevalence esti-
mates are considered and if specific
chronic morbidities are attributed to this
NTD [12]. The variation is also due to
continuous refinement of definitions and
methodologies for burden estimation,
which affects the estimates for all diseases,
injuries, and risk factors and further
complicates the comparison of different
GBD versions. Among the furthest-reach-
ing methodological alterations of GBD
2010 are the shift from incidence- to
prevalence-based DALYs, the abandon-
ment of age weighting and discounting,
the application of refined reference life
tables and disability weights, and the
introduction of comorbidity adjustments
[16].
Some of the greatest variation in the
disease burden estimates over the past
decade has been observed among the
three major intestinal nematode infections
(also known as soil-transmitted helminthi-
ases, i.e., ascariasis, hookworm disease,
and trichuriasis) as well as in schistosomi-
asis. A key reason for this wide variation is
the fact that these helminth infections are
among the most common infections of
humankind [17–19], so small variations in
an assigned disability weight become
amplified by the hundreds of millions of
people estimated to harbor these parasites.
Another reason for variations in some
burden estimates is due to how GBD 2010
uniquely classified certain diseases or
groups of diseases. A prominent example
was the decision to combine the burdens
of cystic echinococcosis and alveolar
echinococcosis into a single estimate (i.e.,
echinococcosis). This was a questionable
decision seeing that the two parasites have
different life cycles, geographic distribu-
tions, and clinical outcomes. Future itera-
tions of the GBD will therefore need to
consider reporting these estimates as
separate conditions, paying greater atten-
tion to the unique attributes of the
individual parasites.
Overall, the NTD community was
dismayed by the previous WHO estimates
between 1999 and 2004 [20], which
assigned DALYs that were equivalent to
conditions of comparatively minor global
health importance for major diseases such
as schistosomiasis [21]. At the other
extreme, the higher DALY estimates for
NTDs elevate the status of these diseases
to a level at which they could be thought
of as the fourth leg to a table built on
HIV/AIDS, tuberculosis, and malaria
[22]. The GBD 2010 is an ambitious
attempt to resolve some of the differences
between earlier estimates (including use of
strictly comparable data and methods for
1990, 2005, and 2010) and to provide a
first attempt at estimating the disease
burden of cysticercosis, echinococcosis,
and rabies as part of the largest ever
burden of disease study [1–3]. The GBD
2010 also provides first-time disease bur-
den estimates for amebiasis, cryptosporid-
iosis, trichomoniasis, scabies, fungal skin
infections, and venomous animal contact
(including snake bite), although they are
Table 1. Estimated DALYs (in millions) of the NTDs from the Global Burden of Disease Study 2010.
Disease
DALYs from GBD 2010 (numbers in parentheses indicate 95% confidence
intervals) [1]
NTDs 26.06 (20.30–35.12)
Intestinal nematode infections 5.19 (2.98–8.81)
Hookworm disease 3.23 (1.70–5.73)
Ascariasis 1.32 (0.71–2.35)
Trichuriasis 0.64 (0.35–1.06)
Leishmaniasis 3.32 (2.18–4.90)
Schistosomiasis 3.31 (1.70–6.26)
Lymphatic filariasis 2.78 (1.8–4.00)
Food-borne trematodiases 1.88 (0.70–4.84)
Rabies 1.46 ((0.85–2.66)
Dengue 0.83 (0.34–1.41)
African trypanosomiasis 0.56 (0.08–1.77)
Chagas disease 0.55 (0.27–1.05)
Cysticercosis 0.50 (0.38–0.66)
Onchocerciasis 0.49 (0.36–0.66)
Trachoma 0.33 (0.24–0.44)
Echinococcosis 0.14 (0.07–0.29)
Yellow fever ,0.001
Other NTDs* 4.72 (3.53–6.35)
* Relapsing fevers, typhus fever, spotted fever, Q fever, other rickettsioses, other mosquito-borne viral fevers, unspecified arthropod-borne viral fever, arenaviral
haemorrhagic fever, toxoplasmosis, unspecified protozoal disease, taeniasis, diphyllobothriasis and sparganosis, other cestode infections, dracunculiasis, trichinellosis,
strongyloidiasis, enterobiasis, and other helminthiases.
doi:10.1371/journal.pntd.0002865.t001
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not listed under the NTD category
(Table 2) [1–3]. One surprising finding
from these estimates was the huge disease
burden that results from cryptosporidiosis
among young children. Together, the
NTDs listed in Table 1 and those in
Table 2 add up to almost 48 million
DALYs. This number is comparable to
tuberculosis (49 million) and is more than
half of the global burden of two of the
world’s major diseases, malaria (83 mil-
lion) and HIV/AIDS (82 million). How-
ever, these comparisons must be conduct-
ed with great care given the large variation
in the quantity and quality of epidemio-
logical data currently available across the
world.
Killers and Disablers
Some of the details of the new disease
burden estimates for NTDs are summa-
rized in Table 3, while the total number of
estimated cases is summarized in Table 4.
Briefly, as stated by Murray et al. (2012),
‘‘DALYs are the sum of two components:
years of life lost due to premature
mortality (YLLs) and years lived with
disability (YLDs)’’ [1]. For many of the
major NTDs, including hookworm disease
and the other intestinal nematode infec-
tions, schistosomiasis, food-borne tremato-
diases, onchocerciasis, cysticercosis, and
trachoma, most (and in some cases all) of
the reported DALYs result from YLDs
(i.e., disability, not deaths) (Figure 1).
These NTDs are genuinely not thought
of as killer diseases, although it has been
noted that some disabling NTDs such as
onchocerciasis, cysticercosis, and food-
borne trematodiases cause excess mortality
associated with blindness, heavy infection
in sighted individuals, hydrocephalus,
stroke, gliomas, ectopic infections, cholan-
giocarcinoma, and other (yet unmeasured)
factors [23–26]. An added feature about
the publication of the YLDs from the
NTDs was the listing of the specific
sequelae that were considered in deriving
these estimates [3], which allows compa-
rability across studies.
According to the GBD 2010 estima-
tions, intestinal nematode infections rank
first in the list of the NTDs for which a
DALY was estimated [27]. Among intes-
tinal nematodes, hookworm disease was
estimated as having the largest YLDs (and
62% of the DALYs). This large contribu-
tion of hookworm disease to the YLDs of
nematodes comes from the inclusion of
recent information linking hookworm
disease to moderate and severe anemia
across several different populations, in-
cluding children and pregnant women
[28,29]. On the other hand, important
comorbidity effects resulting from hook-
worm disease and malaria coinfections
[30–32] and the deaths from these condi-
tions were attributed to malaria in the
GBD 2010, reducing the apparent YLLs
of hookworm infections.
Schistosomiasis was estimated to rank
second in terms of YLDs (and right behind
the intestinal nematode infections in terms
of prevalence). Schistosomiasis was one of
the NTDs that generated the most con-
troversy and debate in the GBD 2010.
Since 2005, important information has
been generated about the effects of
schistosomiasis that result in chronic pain,
inflammation, malnutrition, and exercise
intolerance, among other morbid sequelae
[12,21,33], which under some scenarios
generated DALY estimates that exceeded
those of malaria or other better-known
conditions [12]. However, many of these
aspects were not accepted into the GBD
2010, in part because of disagreements
about the long-term health importance
and actual YLLs caused by these elements.
Fueling the schistosomiasis controversy
even further were previously published
annual mortality estimates for schistoso-
miasis (i.e., 280,000 in Africa alone) [33]
suggesting that the number of people killed
from this disease was at least 20 times
higher than indicated in GBD 2010 [34].
In addition, there is new information on
the links between female urogenital schis-
tosomiasis and the risk of acquiring HIV/
AIDS [35]. The discussions surrounding
the burden of schistosomiasis may just be
the start of future investigations on how to
best attribute parts of the burden of
chronic diseases and sequelae to NTDs.
Only through such debates will the
estimations of the burden of disease
further improve.
There are two major NTDs linked to
blindness—trachoma and onchocerciasis.
For trachoma, the DALYs only consider
disease due to active infection and do not
consider blindness that exists even after
removal of the infection. For onchocerci-
asis, the DALYs do not consider the excess
mortality due to blindness [23] and likely
underestimate the effects of onchocercal
skin disease. Furthermore, the onchocer-
ciasis estimates have ignored the burden in
the Americas and low-endemic African
countries, which may now be relatively
small compared to the burden in Africa
but was not negligible in 1990. Hence, in
both instances the disease burdens from
blinding NTDs may represent underesti-
mates.
Table 2. Other NTDs in the Global Burden of Disease Study 2010 not listed in the ‘‘NTD and malaria’’ category.1
Disease
DALYs from GBD 2010 in millions (numbers in parentheses
indicate 95% confidence intervals) [1]
Cryptosporidiosis 8.37 (6.52–10.35)
Cholera 4.46 (3.34–5.80)
Animal contact (venomous) 2.72 (1.54–4.80)
Amebiasis 2.24 (1.73–2.84)
Fungal skin diseases 2.30 (0.72–5.27)
Scabies 1.58 (0.80–2.79)
Trichomoniasis 0.17 (0.01–0.53)
Leprosy 0.006 (0.002–0.11)
Total 21.84
Total of NTDs in Table 1 (from GBD 2010) and NTDs in Table 2 47.90
1The table provides numbers of DALYs in millions as calculated in GBD 2010 [1]. The diseases are not listed as NTDs in GBD 2010 and, with the exception of leprosy,
these diseases are also not on the WHO list of 17 NTDs [5]. However, these conditions (as well as some other diarrheal diseases) are considered by PLOS Neglected
Tropical Diseases [6].
doi:10.1371/journal.pntd.0002865.t002
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Finally, in terms of YLDs, important
‘‘newcomers’’ on the GBD scene were the
food-borne trematodiases, cysticercosis,
and echinococcosis, which must now be
recognized as important causes of global
disability. Still, no deaths were ascribed to
either clonorchiasis or opisthorchiasis (two
of the key food-borne trematode infec-
tions) in the GBD 2010, despite the strong
evidence base linking these liver fluke
infections to cholangiocarcinoma in
Southeast Asia and elsewhere [36,37].
Similarly, the YLLs from cysticercosis are
most likely underestimated. Indeed, a
recent systematic review of the literature
showed the proportion of neurocysticerco-
sis patients under care who died during
their follow-up could vary from 0.9% to
18.5% [27]. Mostly due to a lack of
available data on a global scale, the
current estimate for cysticercosis is limited
to its role in epilepsy in endemic countries
and does not yet include the role of this
infection in causing severe chronic head-
aches and hydrocephalus, depressive dis-
orders, stroke, gliomas, and other neuro-
logical sequelae [24].
Among the killer NTDs, almost all of
the DALYs due to diseases such as rabies,
dengue, and African trypanosomiasis re-
sulted from YLLs, and practically no
disability was associated with nonlethal
effects from these conditions (YLDs)
(Figure 1). However, for dengue, consid-
erable evidence now points to a potentially
higher percentage of DALYs due to YLDs
(,25%) as a result of underreporting of
nonfatal cases [38,39]. Similarly, for
leishmaniasis the DALY estimates mostly
considered the large number of deaths
resulting from visceral leishmaniasis but
included virtually nothing from the dis-
ability of cutaneous leishmaniasis. This
finding is a debatable point given the
evidence linking disfiguring cutaneous
(and mucocutaneous) leishmaniasis on
the face to stigma and its impact on girls
and women [40]. In addition, for African
trypanosomiasis there is also a long-term
disease burden resulting from nonfatal
consequences, including those suffered by
survivors who are eventually treated [41].
Chagas disease was one of the important
NTDs whose DALYs were roughly equal-
ly distributed between YLDs and YLLs.
Trends
Figure 2 depicts the ranking of the
different NTDs in 1990 as compared to
2010. Although the estimates for both years
stem from GBD 2010 and are therefore
extrapolated by using the same methodolo-
gy, they must be interpreted with great care
given that the accuracy of the underlying
data may have changed through time, with
more accurate diagnostic tests becoming
available in recent years. The survey
locations for frequency data may also have
varied between the two periods.
As shown in Figure 2, ascariasis exhib-
ited the largest decrease in DALYs,
possibly as a consequence of deworming
and socioeconomic development, although
it could also reflect the fact that many
follow-up studies may have been conduct-
ed in areas where such control programs
took place. In addition, ascariasis exhibit-
ed the greatest decrease in rank, whereas
the rankings for trichuriasis and hook-
worm disease remained constant. The
basis for this difference among the intes-
tinal nematode infections is not known,
although it may be related to the differen-
tial susceptibility of the different helminth
species to benzimidazole anthelmintics
[42]. It is anticipated that helminth control
through mass drug administration and
improved access to clean water and
sanitation may alter epidemiologic pat-
terns and disease prevalence in the coming
years [43].
African trypanosomiasis and rabies (and
some other NTDs) were also greatly
diminished, the former possibly due to
increased access to public health control in
association with the resolution of some
civil and international conflicts in sub-
Saharan Africa [44]. In contrast, DALY
Table 4. Expected number of cases in 2010 and 95% confidence intervals of the neglected tropical diseases (mean and
uncertainty) as extrapolated from the Global Burden of Disease Study 2010.
Disease Number of cases 95% confidence intervals Selected comments
Ascariasis1 819 million 772–892 million Total number of cases
Trichuriasis1 465 million 430–508 million Total number of cases
Hookworm disease1 439 million 406–480 million Total number of cases
Schistosomiasis 252 million 252–252 million Total number of cases
Onchocerciasis 30.4 million 27.3–33.6 million Total number of cases with adult worms*
Lymphatic filariasis 36 million 34–39 million Lymphedema and/or hydrocele only
Food-borne trematodiases 16 million 7–41 million Heavy and cerebral infections only
Cutaneous leishmaniasis 10 million 8–13 million Total number of cases
Chagas disease 7.5 million 2.5–12.4 million Symptomatic cases only
Trachoma 4.4 million 3.5–5.5 million Low vision and blindness cases only
Cysticercosis 1.4 million 1.3–1.6 million Epilepsy cases only
Echinococcosis 1.1 million 0.6–2.1 million Symptomatic liver, lung, and central nervous system cases
only
Dengue 179,000 cases 109,000–299,000 Incident (acute) symptomatic cases only
Visceral leishmaniasis 76,000 cases 61,000–93,500 Total number of cases
African trypanosomiasis 37,000 cases 9,000–106,000 Symptomatic cases only
Rabies 1,100 cases 600–2,000 Incident cases
Yellow fever 100 cases 0–100 cases Incident cases
* This number includes 14.6 million people (13.2–16.1 million) with detectable skin microfilariae.
1These are updated estimates recently published in Pullan et al. [27].
doi:10.1371/journal.pntd.0002865.t004
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estimates for schistosomiasis, lymphatic
filariasis, and trachoma appear to have
increased over the past 20 years. The
underlying bases for these increases in-
clude population growth, ecological trans-
formations (e.g., construction of large
dams and irrigation systems), and possibly
increased surveillance, although it is an-
ticipated that as integrated parasitic dis-
ease control and preventive chemotherapy
initiatives progress and access to clean
water and sanitation increases, we should
witness a reduction in several of these
disease burden estimates in future years
[43]. For dengue, urbanization and in-
creases in global commerce and travel
contribute to the emergence of this
important disease [45,46], but increased
access to diagnostic tools may also play a
role. Since the publication of the GBD
2010, a new estimate suggests that as
many as 390 million cases of dengue
infections now occur annually [47], more
than three times the previous estimates by
the WHO.
Geographic Distribution
Comparison in the geographical dis-
tribution of NTDs must also be conduct-
Figure 2. Global trends in DALYs from NTDs, 1990 to 2010. *Estimation of percent (%) change is not from the means. Each metric in this
figure is estimated on 1000 times in the modeling process, and then causes that have a high degree of uncertainty in their draw estimates can have
skewed % change results. Abbreviations: UI, unit interval.
doi:10.1371/journal.pntd.0002865.g002
Figure 1. Fractions of YLD and YLL (as components of DALYs) for each of the NTDs. Also included in this graph are ‘‘other NTDs.’’
doi:10.1371/journal.pntd.0002865.g001
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ed with great care since the quality and
quantity of data available will depend on
where epidemiological studies have been
conducted. In addition, within each
country, the reported country-level
DALYs may be based on surveys con-
ducted specifically in areas where an
infection is known to be endemic, which
may increase their relative importance as
compared to countries where surveys
have not been conducted due to a lack
of funding or have been conducted in
both endemic and nonendemic areas of
the country. It is also important to
emphasize that many NTDs are of local
or of focal importance, often affecting
marginalized populations who may not
be recognized as national priorities [48].
However, keeping these limitations in
mind, the GBD 2010 suggests that there
exists an extensive geographic distribu-
tion of the NTDs, with sub-Saharan
Africa representing the highest DALY
rate per 100,000 individuals from
NTDs—in part because of their high
prevalence together with coinfections
that result from hookworm disease,
schistosomiasis, onchocerciasis, and Afri-
can trypanosomiasis [1]. Oceania also
has a disproportionate share of NTDs
(especially from hookworm disease in
Papua New Guinea), as does Southeast
Asia, South Asia, and tropical Latin
America [1]. Overall the largest (net)
number of DALYs from NTDs occurs in
Asia (Figure 3). It has been noted that the
largest number of cases of many of the
high-burden NTDs actually occur in the
large emerging-market Asian countries
such as China, India, and Indonesia, as
well as other countries of the group of 20
(G20) nations [49].
In many Latin American countries,
Chagas disease is the predominant
NTD. Exceptions are several countries
where either intestinal nematode infec-
tions predominate (e.g., Colombia, Ecua-
dor, and Venezuela) or Chagas may be
underreported, and Haiti and the Do-
minican Republic, where dengue is the
largest source of DALYs. In Bolivia and
Peru, food-borne trematodiases rank
closely with Chagas disease as the leading
NTDs, while emerging information about
Chagas disease in the United States [50]
may eventually make it an important
NTD there as well. Schistosomiasis is
the predominant NTD among sub-Sa-
haran African countries, except in select-
ed nations where leishmaniasis (e.g.,
Sudan), African trypanosomiasis (e.g.,
Democratic Republic of the Congo,
Central African Republic, and Chad),
onchocerciasis (e.g., Cameroon), lymphat-
ic filariasis (e.g., Senegal and Guinea-
Bissau), intestinal nematode infections
(South Africa, Botswana, and Namibia),
or rabies (Niger) rank higher. In the
Middle East, leishmaniasis is an impor-
tant NTD, while rabies is the predomi-
nant NTD in Afghanistan. In Asia,
leishmaniasis is the leading NTD in India;
food-borne trematodiases predominate in
China, North Korea, and Japan; and
intestinal nematode infections are the
leading NTDs in much of Southeast Asia
(with the exception of dengue in Lao
PDR) and Papua New Guinea.
Missing in Action
There remain some important NTDs
for which there are no or limited published
disease-burden estimates. These include
strongyloidiasis [51], toxocariasis [52], and
loiasis, which are among the most com-
mon parasitic nematode infections world-
wide, as well as toxoplasmosis [53], an
important maternal-child protozoan infec-
tion that has recently been linked to
schizophrenia in immune-competent peo-
ple and to issues of mental health;
leptospirosis, a major bacterial infection;
and podoconiosis, a noninfectious condi-
tion. In order to estimate the burden
subsumed and named as ‘‘other NTDs’’,
Figure 3. DALYs: Number by disease and for the 21 regions in 2010 (in thousands).
doi:10.1371/journal.pntd.0002865.g003
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the respective cases of death were modeled
by using a Cause of Death Ensemble
model (CODEm) tool [2,54], and then the
ratio of YLLs to YLDs as derived from the
rest of the NTDs was applied to extrap-
olate the respective YLDs.
Concluding Statements and
Future Directions
An important overriding conclusion of
the GBD 2010 is the apparent global
shift away from communicable to non-
communicable diseases (NCDs) [1,55].
Such a conclusion must be tempered by
the knowledge that many NTDs are
actually underlying causes of the so-
called NCDs. In 2008, several NCDs
were described, including cancer, car-
diovascular disease, and liver disease,
that result from chronic long-standing
NTDs or from past infections with NTDs
such as cysticercosis [56]. With regards
to cancer, a new review has identified a
substantial burden that can be attributed
to infectious diseases [57]. These esti-
mates suggest that, globally, 16% of
cancers are caused by underlying infec-
tious agents, and in some developing
regions such as sub-Saharan Africa,
almost one-third of cancers are caused
by infections [57]. In terms of the NTDs,
it is known that Schistosoma haematobium
(the cause of urogenital schistosomiasis)
and three of the major liver flukes—
Opisthorchis viverrini, O. felineus, and
Clonorchis sinensis—are potent carcino-
gens responsible for a substantial but
largely unknown burden of bladder
cancer and cholangiocarcinoma, respec-
tively [36,58,59]. The burden of cardio-
vascular disease attributed to NTDs has
been recently summarized [60], as have
some interesting links between NTDs
and chronic liver disease [61] and
between onchocerciasis and epilepsy
[62]. As new information is obtained,
the number of NCD YLLs and YLDs
attributed to NTDs will almost certainly
increase.
The GBD 2010 is not intended to be
the final word on the global disease
burden resulting from NTDs. Additional
research is needed for almost all of the
NTDs, and it is expected that as new
information becomes available it can be
incorporated into new DALY estimates.
For example, the annual number of
officially reported dengue cases in eight
endemic countries in the Americas and
Asia (574,000) is almost three times the
episodes estimated by GBD 2010 (Table 4)
[63]. Other important examples include
the nonlethal consequences of African
trypanosomiasis, dengue, and leishmania-
sis that will add a larger YLD component
to disease burdens for these conditions, as
well as the deaths that result from
cysticercosis, food-borne trematodiases,
hookworm disease, onchocerciasis, and
schistosomiasis, among others, which will
add YLLs. The GBD 2010 will be updated
regularly, which might also allow epide-
miologists and policy makers to observe
spatiotemporal and presumably declining
trends in ascariasis, African trypanosomi-
asis, lymphatic filariasis, onchocerciasis,
trachoma, and possibly other NTDs as
a result of preventive chemotherapy
and other control interventions. In
so doing, a sincere hope is that the
GBD 2010 can become a living and
breathing document with the flexibility to
adapt and change and can ultimately
resolve discrepancies and controversies
on the true disease burden resulting from
NTDs and diseases, injuries, and risk
factors.
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